Company overview. Wockhardt Limited (NSE: WOCKPHARMA; BSE: 532300) is an Indian pharmaceutical and biotechnology company founded in 1967 by Dr. Habil Khorakiwala, with registered operations dating to 1973 and incorporation as Wockhardt Ltd. in 1999. It is headquartered at Wockhardt Towers, Bandra-Kurla Complex, Mumbai, and is publicly listed — not a subsidiary. Size estimates vary by source: recent filings and market data put revenue at roughly ₹33–35 billion (about US$350–400 million) for FY2025–26, with employee counts cited between roughly 2,500 and 4,100 depending on the reporting date. Market capitalization has been reported in the hundreds of billions of rupees on Indian exchanges.
Products / operations. Wockhardt operates as a genuine, large-scale manufacturer. It makes branded and generic finished formulations, active pharmaceutical ingredients (APIs), biopharmaceuticals, nutrition products and vaccines, with manufacturing in India, the UK, Ireland, France and the US (including Morton Grove Pharmaceuticals), and subsidiaries including Wockhardt Bio AG in Switzerland. Therapeutic strengths include anti-infectives, pain management, diabetes, nephrology, neuropsychiatry and dermatology. Its biotech line includes recombinant human insulin (Wosulin), insulin glargine (Glaritus) and insulin delivery devices. Its discovery program focuses on novel antibiotics against antimicrobial resistance, including zidebactam/cefepime (Zaynich), nafithromycin (Miqnaf) and ertapenem/zidebactam (Odrate). It also runs Wockhardt Hospitals and offers contract manufacturing/custom research.
Patent-litigation posture. The tracked data show Wockhardt as a defendant in two 2015 cases and never as a plaintiff — the signature of an operating company defending infringement claims rather than an NPE. Both tracked suits were filed in the US District Court for the District of New Jersey, not a plaintiff-friendly venue such as the Eastern District of Texas. There is no evidence in the case data of Wockhardt asserting patents offensively.
Notable cases. Both tracked matters are Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al. (D.N.J., filed July 17, 2015), Hatch-Waxman ANDA litigation over generic sodium oxybate (Xyrem). Jazz's filings state that it sued after Wockhardt Bio AG submitted an ANDA and a Paragraph IV certification. The parties settled in April 2016; Wockhardt also filed IPR petitions, which were terminated after settlement. Jazz disclosed that the settlement licensed Wockhardt to sell generic Xyrem on or after December 31, 2025, subject to confidential terms.